This resubmission will investigate the associations between exposure to arsenic and other environmental exposures on vascular function and platelet activity among newly diagnosed untreated patients with type 2 diabetes (T2D). Candidate: The primary objective of this application is to support Dr. Jonathan Newman's career development into an independent translational cardiovascular physician-scientist in the field of environmental medicine, diabetes and cardiovascular disease (CVD). Dr. Newman's career goal is to integrate environmental medicine with cardiovascular care such that cardiovascular outcomes can be improved, particularly for patients with T2D and an elevated risk of CVD. His proposed training plan focuses on 4 areas: (1) research methods and analysis; (2) translational laboratory methods; (3) vascular structure and function; 4) environmental medicine and epidemiology. Environment: New York University (NYU) Medical Center is a national leader in research and is one of the top 20 medical schools in NIH funding. The Department of Environmental Medicine at NYU is one of the nation's oldest and foremost centers for research into the health effects of environmental pollution. The Division of Cardiology is a top-ranked division nationally, with the largest research budget in the Department of Medicine at NYU. Research: The population of patients with T2D continues to grow. CVD is the leading cause of morbidity and mortality in patients with T2D. There remains an unmet clinical need to identify modifiable risk factors for CVD in patients with T2D. Exposure to inorganic arsenic and other environmental toxicants may be novel targets for CVD risk reduction for these patients. However, there have been no clinical studies of environmental exposures on vascular function and thrombotic risk among untreated patients newly diagnosed with T2D. To investigate the role of inorganic arsenic and other environmental exposures on vascular function and platelet activity in an urban T2D population, we propose to study a prospective cohort of 100 newly diagnosed individuals with T2D, without the confounding effects of diabetes treatment.
Our specific aims are to: (1) evaluate the association between inorganic arsenic exposure and measures of vascular function; (2) evaluate the association between inorganic arsenic exposure and measures of thrombotic risk; and (3) explore the independent association between environmental exposures other than arsenic and measures of vascular function and thrombotic risk. Our proposed innovative study will prospectively assess the association between biomarkers of vascular and platelet function and environmental exposures, a potential novel risk factor for CVD in patients with T2D. The proposed study will support a robust training plan in translational research and environmental and cardiovascular disease epidemiology, and will support the development of the PI into an independent translational physician-scientist. There is an unmet need to address the excess risk of CVD among patients with T2D, and this study represents an innovative approach to a novel class of risk factors.
Cardiovascular disease is the leading cause of morbidity and mortality for patients with type 2 diabetes. The number of patients with type 2 diabetes in the United States continues to grow. Exposure to inorganic arsenic and other environmental toxicants is common, and may be important for the pathogenesis of cardiovascular disease especially in patients with diabetes. To better understand the links between environmental exposures and cardiovascular disease, we propose to study vascular function and thrombotic risk in a cohort of untreated, newly diagnosed patients with type 2 diabetes.
|Wilcox, Tanya; Newman, Jonathan D; Maldonado, Thomas S et al. (2018) Peripheral vascular disease risk in diabetic individuals without coronary heart disease. Atherosclerosis 275:419-425|
|Gianos, Eugenia; Schoenthaler, Antoinette; Guo, Yu et al. (2018) Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) trial. Am Heart J 199:37-43|
|Schwartzbard, Arthur Z; Newman, Jonathan D; Weintraub, Howard S et al. (2018) The 2017 high blood pressure clinical practice guideline: The old and the new. Clin Cardiol 41:279-281|
|Newman, Jonathan D; Vani, Anish K; Aleman, Jose O et al. (2018) The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review. J Am Coll Cardiol 72:1856-1869|
|Jelani, Qurat-Ul-Ain; Harchandani, Bhisham; Cable, Ritchard G et al. (2018) Effects of serial phlebotomy on vascular endothelial function: Results of a prospective double-blind randomized study. Cardiovasc Ther :e12470|
|Newman, Jonathan D; Wilcox, Tanya; Smilowitz, Nathaniel R et al. (2018) Influence of Diabetes on Trends in Perioperative Cardiovascular Events. Diabetes Care 41:1268-1274|
|Rodriguez, Valentina; Newman, Jonathan D; Schwartzbard, Arthur Z (2018) Towards more specific treatment for diabetic dyslipidemia. Curr Opin Lipidol 29:307-312|
|Shah, Binita; Ganguzza, Lisa; Slater, James et al. (2017) The Effect of a Vegan versus AHA DiEt in Coronary Artery Disease (EVADE CAD) trial: study design and rationale. Contemp Clin Trials Commun 8:90-98|
|Newman, Jonathan D; Schwartzbard, Arthur Z; Weintraub, Howard S et al. (2017) Primary Prevention of Cardiovascular Disease in Diabetes Mellitus. J Am Coll Cardiol 70:883-893|
|Nhek, Sokha; Clancy, Robert; Lee, Kristen A et al. (2017) Activated Platelets Induce Endothelial Cell Activation via an Interleukin-1? Pathway in Systemic Lupus Erythematosus. Arterioscler Thromb Vasc Biol 37:707-716|
Showing the most recent 10 out of 14 publications